159 related articles for article (PubMed ID: 22352188)
1. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
[TBL] [Abstract][Full Text] [Related]
2. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
3. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
4. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
[TBL] [Abstract][Full Text] [Related]
5. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Kuiper R; van Duin M; van Vliet MH; Broijl A; van der Holt B; El Jarari L; van Beers EH; Mulligan G; Avet-Loiseau H; Gregory WM; Morgan G; Goldschmidt H; Lokhorst HM; Sonneveld P
Blood; 2015 Oct; 126(17):1996-2004. PubMed ID: 26330243
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
7. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
[TBL] [Abstract][Full Text] [Related]
8. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
10. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
Kjeldsen E
Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
[TBL] [Abstract][Full Text] [Related]
11. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Merz M; Jauch A; Hielscher T; Bochtler T; Schönland SO; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Hillengass J; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf IGH; Scheid C; Haenel M; Weisel KC; Goldschmidt H
Blood Adv; 2018 Jan; 2(1):1-9. PubMed ID: 29344579
[TBL] [Abstract][Full Text] [Related]
14. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
Goldschmidt H; Lokhorst HM; Mai EK; van der Holt B; Blau IW; Zweegman S; Weisel KC; Vellenga E; Pfreundschuh M; Kersten MJ; Scheid C; Croockewit S; Raymakers R; Hose D; Potamianou A; Jauch A; Hillengass J; Stevens-Kroef M; Raab MS; Broijl A; Lindemann HW; Bos GMJ; Brossart P; van Marwijk Kooy M; Ypma P; Duehrsen U; Schaafsma RM; Bertsch U; Hielscher T; Jarari L; Salwender HJ; Sonneveld P
Leukemia; 2018 Feb; 32(2):383-390. PubMed ID: 28761118
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
18. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
19. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Hose D; Rème T; Meissner T; Moreaux J; Seckinger A; Lewis J; Benes V; Benner A; Hundemer M; Hielscher T; Shaughnessy JD; Barlogie B; Neben K; Krämer A; Hillengass J; Bertsch U; Jauch A; De Vos J; Rossi JF; Möhler T; Blake J; Zimmermann J; Klein B; Goldschmidt H
Blood; 2009 Apr; 113(18):4331-40. PubMed ID: 19171872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
